KCM
TRIB

Keane Capital Management’s Trinity Biotech TRIB Stock Holding History

Keane Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-367
Closed -$630K – 26
2015
Q3 		$630K Buy
367
+93
+34% +$224K 0.83% 42
2015
Q2 		$743K Sell
274
-361
-57% -$938K 0.76% 46
2015
Q1 		$1.83M Buy
635
+170
+37% +$471K 1.79% 28
2014
Q4 		$1.22M Sell
465
-2
-0.4% -$5.17K 1.18% 41
2014
Q3 		$1.28M Buy
+467
New +$1.52M 1.23% 45

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

Keane Capital Management's TRIB Position: Q4 2015 in Review

Keane Capital Management sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 367 shares — an estimated $630K sold.

Keane Capital Management first reported a position in TRIB in Q3 2014 and held it in 5 quarters. The position peaked at $1.83M in Q1 2015. 81 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

  • Keane Capital Management reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
  • Keane Capital Management sold 367 Trinity Biotech shares in Q4 2015, an estimated $630K.
  • Keane Capital Management first reported a position in Trinity Biotech in Q3 2014 and held it in 5 quarters.
  • Keane Capital Management's Trinity Biotech position peaked at $1.83M in Q1 2015.
  • 81 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on Keane Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.